Allergy Conjunctivitis Market Report 2025

The allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.51 billion in 2024 to $2.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing incidence of allergic conditions, advancements in research and development, changing lifestyles and environmental factors, expansion of patient awareness, collaborations and partnerships, healthcare infrastructure development.

The allergy conjunctivitis market size is expected to see strong growth in the next few years. It will grow to $3.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing global allergy burden, personalized medicine approaches, growing geriatric population, biotechnological innovations, expanding healthcare access in developing regions, regulatory support and approvals. Major trends in the forecast period include integration of novel drug delivery technologies, emphasis on patient education and awareness, development of combination therapies, incorporation of artificial intelligence (ai) in diagnosis, rise in environmental allergen management solutions.

The increasing exposure to air pollutants and chemicals is projected to drive growth in the allergy conjunctivitis market in the coming years. Human eyes, being one of the most sensitive parts of the body, are continually at risk due to persistent exposure to harmful substances present in air pollution. Prolonged exposure to airborne pollutants and chemicals can lead to various eye problems, including allergic conjunctivitis, burning sensations, watering, blurred vision, redness, itching, and chronic discomfort, necessitating treatments. For example, in April 2022, the World Health Organization, a Switzerland-based international public health agency, reported that nearly the entire global population (99%) is exposed to air that exceeds the organization's air quality standards, posing significant health risks. Over 6,000 cities across 117 countries are now monitoring air quality, yet residents in these areas continue to inhale unhealthy levels of fine particulate matter and nitrogen dioxide, with individuals in low and middle-income countries facing the highest exposure levels. Thus, the rise in exposure to air pollutants and chemicals is fueling the growth of the allergy conjunctivitis market.

The prevalence of eye disorders is another key driver propelling the growth of the allergy conjunctivitis market. Eye disorders encompass various conditions affecting eye structure or function, resulting in impaired vision or related symptoms. Allergic conjunctivitis stands as a substantial contributor to these eye disorders, particularly when triggered by allergic reactions to environmental elements like pollen, dust, or pet dander. The surge in environmental pollutants and chemicals has led to an uptick in cases of allergic conjunctivitis. Globally, over 2.2 billion people are affected by near or distance vision impairment, with various conditions like cataracts, refractive errors, age-related macular degeneration, glaucoma, and diabetic retinopathy, as per the World Health Organization's report. This prevalence of eye disorders contributes significantly to the growth of the allergy conjunctivitis market.

Product innovation emerges as a pivotal trend driving the allergy conjunctivitis market. Key companies in this sector are intensifying their focus on developing innovative and advanced products to bolster their market presence. For instance, Allergan, an Irish-US-based medical company, introduced LASTACAFT, an eye allergy drop in March 2022. This brand of eye drops delivers relief from itchiness and allergies within three minutes and offers sustained relief for up to 16 hours. LASTACAFT, an antihistamine eye drop, targets histamines triggering ocular itching, effectively calming allergic responses caused by pollen, ragweed, grass, animal hair, and dander in individuals aged two and above. The launch of such innovative solutions expands the company's retail eye drop portfolio, ensuring quality eye care products for consumers.

Major companies in the allergy conjunctivitis market are actively pursuing strategic partnerships to fortify their market presence. These business collaborations involve structured affiliations between two or more enterprises, typically established through formal business agreements or contracts. For instance, in May 2022, AffaMed Therapeutics, a China-based biopharmaceutical company, entered into a partnership with Primal Chemical. This collaboration aims to enhance AffaMed's capabilities, enabling healthcare institutions and practitioners to offer patients more treatment options, including IOLs and DEXTENZA, specifically for patients in Hong Kong and Macau. Primal Chemical, based in Hong Kong, specializes in chemical solutions.

In July 2023, Harrow Health, a prominent U.S.-based company focused on the ophthalmic healthcare market, made an acquisition of the branded ophthalmic portfolio from Santen Holdings U.S. Inc. This strategic acquisition empowers Harrow Health to solidify its position as a leading player among top-tier U.S. ophthalmic pharmaceutical companies. The addition of Santen's branded portfolio significantly enriches Harrow Health's offerings, establishing it as one of the most comprehensive portfolios available in the U.S. market. Santen Holdings U.S. Inc. operates as a U.S.-based provider of ophthalmology solutions and is dedicated to human eye health.

Major companies operating in the allergy conjunctivitis market are Allergan PLC, AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alcon Inc., Alembic Pharmaceuticals Ltd., Atopix Therapeutics Ltd., Auven Therapeutics Management LLLP, Bausch & Lomb, Cipla Ltd., Grevis Pharmaceutical Private Limited, Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd., Novartis AG, Ocular Therapeutix Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Laboratoires Thea SAS, Aciex Therapeutics Inc., Bausch Health Companies Inc., C.H. Boehringer Sohn AG & Co. KG, Eyevance Pharmaceuticals LLC, Johnson & Johnson Services Inc., Mylan N.V., Nicox S.A., Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Shire PLC, Teva Pharmaceutical Industries Ltd., Zydus Cadila.

North America was the largest region in the allergy conjunctivitis market share in 2024. The regions covered in the allergy conjunctivitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergy conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Allergic conjunctivitis is the inflammation of the conjunctiva, the membrane covering the inside of eyelids and the white part of the eyeball. This inflammation is triggered by an allergic reaction to substances like pollen or mold spores. Symptoms of allergic conjunctivitis include red, itchy, and watery eyes.

The main drug classes used for treating allergic conjunctivitis are antihistamines and mast cell stabilizers, corticosteroids, and others. Antihistamines and mast cell stabilizers are medications, available either by prescription or over-the-counter, that work to inhibit the physiological action of histamines. The severity of the disease can range from mild to severe, and medications for conjunctivitis are distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

The allergy conjunctivitis market research report is one of a series of new reports that provides allergy conjunctivitis market statistics, including allergy conjunctivitis industry global market size, regional shares, competitors with allergy conjunctivitis market share, detailed allergy conjunctivitis market segments, market trends, and opportunities, and any further data you may need to thrive in the allergy conjunctivitis industry. This allergy conjunctivitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allergy conjunctivitis market consists of sales of therapeutics that are used to treat inflammation of eyes caused due to allergens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.